PT1487828E - Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases - Google Patents

Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases Download PDF

Info

Publication number
PT1487828E
PT1487828E PT03745294T PT03745294T PT1487828E PT 1487828 E PT1487828 E PT 1487828E PT 03745294 T PT03745294 T PT 03745294T PT 03745294 T PT03745294 T PT 03745294T PT 1487828 E PT1487828 E PT 1487828E
Authority
PT
Portugal
Prior art keywords
morpholinyl
treatment
urea derivatives
inflamatory diseases
inflamatory
Prior art date
Application number
PT03745294T
Other languages
Portuguese (pt)
Inventor
Colin David Eldred
Rachael Ann Ancliff
Caroline Mary Cook
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT1487828E publication Critical patent/PT1487828E/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT03745294T 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases PT1487828E (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds

Publications (1)

Publication Number Publication Date
PT1487828E true PT1487828E (en) 2009-01-06

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03745294T PT1487828E (en) 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases

Country Status (23)

Country Link
US (1) US7622464B2 (en)
EP (1) EP1487828B1 (en)
JP (1) JP4465195B2 (en)
KR (1) KR20040093488A (en)
CN (1) CN1656092A (en)
AR (1) AR040403A1 (en)
AT (1) ATE413399T1 (en)
AU (1) AU2003226757A1 (en)
BR (1) BR0308780A (en)
CA (1) CA2480106A1 (en)
CY (1) CY1108652T1 (en)
DE (1) DE60324535D1 (en)
DK (1) DK1487828T3 (en)
ES (1) ES2315519T3 (en)
IL (1) IL164047A0 (en)
IS (1) IS7444A (en)
MX (1) MXPA04009459A (en)
NO (1) NO20044448L (en)
PT (1) PT1487828E (en)
RU (1) RU2004127928A (en)
SI (1) SI1487828T1 (en)
TW (1) TW200400035A (en)
WO (1) WO2003082861A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
US20050026844A1 (en) 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
ES2564167T3 (en) * 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugates of long-acting polypeptides containing a tetrazole fraction
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006028284A1 (en) 2004-09-08 2006-03-16 Mitsubishi Pharma Corporation Morpholine compound
CA2584342C (en) 2004-10-20 2013-04-30 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
AR058347A1 (en) 2005-12-15 2008-01-30 Cytokinetics Inc ENTITIES CHEMIES COMPOSITIONS AND METHODS
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (en) * 2006-03-13 2008-04-30 Univ California UREA INHIBITORS CONFORMATIONALLY RESTRICTED OF SOLUBLE HYDROLASSE EPOXIDE
EP2182809B1 (en) 2007-08-27 2018-01-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (en) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Method of obtaining ethyl 1,2,4-oxadiazole-5-carboxylates
CN107362362B (en) * 2017-07-20 2019-01-01 复旦大学 SIRT1 inhibitor is preventing and treating the application in radioactive intestines problem
EP4178948A2 (en) * 2020-07-29 2023-05-17 Universidade de Santiago de Compostela Functionalized isonitriles and products, preparation and uses thereof
WO2022031735A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (en) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 A kind of synthetic method of 3-aminomethyl-1-H pyrazole

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (en) 1990-11-30 2000-09-11 三井化学株式会社 Novel heterocyclic compound and pharmaceutical composition containing the same
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
EP0759918A1 (en) 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
CA2195443A1 (en) 1994-07-20 1996-02-01 Bernhard Kohl Piperazine thiopyridines for controlling helicobacter bacteria
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (en) 1997-08-01 1999-03-10 Recordati Chem Pharm 1- (N-PHENYLAMINOALKYL) PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
WO1999021848A2 (en) 1997-10-27 1999-05-06 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
HK1038749A1 (en) 1998-09-30 2002-03-28 纽罗根公司 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
HUP0303107A2 (en) * 2000-09-29 2004-03-01 Glaxo Group Ltd. Compounds useful in the treatment of inflammatory diseases, process for their preparation and pharmaceutical compositions containing them
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases

Also Published As

Publication number Publication date
WO2003082861A3 (en) 2004-03-11
JP2005526815A (en) 2005-09-08
WO2003082861A2 (en) 2003-10-09
CA2480106A1 (en) 2003-10-09
US7622464B2 (en) 2009-11-24
CN1656092A (en) 2005-08-17
CY1108652T1 (en) 2014-08-13
TW200400035A (en) 2004-01-01
AU2003226757A1 (en) 2003-10-13
RU2004127928A (en) 2005-06-27
DK1487828T3 (en) 2009-02-02
EP1487828B1 (en) 2008-11-05
DE60324535D1 (en) 2008-12-18
AR040403A1 (en) 2005-04-06
KR20040093488A (en) 2004-11-05
EP1487828A2 (en) 2004-12-22
US20060063765A1 (en) 2006-03-23
IS7444A (en) 2004-09-13
IL164047A0 (en) 2005-12-18
ATE413399T1 (en) 2008-11-15
JP4465195B2 (en) 2010-05-19
BR0308780A (en) 2004-12-28
MXPA04009459A (en) 2005-01-25
SI1487828T1 (en) 2009-04-30
NO20044448L (en) 2004-10-26
ES2315519T3 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
SI1487828T1 (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2003286567A8 (en) Methods for the treatment of skin disorders
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
PL1656346T3 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
NO20052894D0 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
AU2003300791A1 (en) Combination therapy for the treatment of pain
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
PL1670482T3 (en) Use of ciclesonide for the treatment of respiratory diseases
GB0213869D0 (en) The treatment of pain
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
LT1496918T (en) Use of sodium meta-arsenite for the treatment of tumours
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
GB2410744B (en) Kinase inhibitors for the treatment of disease
GB0201025D0 (en) The treatment of degenerative diseases
EP1488800A4 (en) Agent for the treatment of protozoal diseases